Skip to main content
Loading

EvastBio Inc

February 10, 2025
Regenerative Medicine
EvastBio Inc
EVast Bio is a US-based clinical-stage biotech spinoff and Delaware C Corp pioneering the development of small Extracellular Vesicle (sEV) therapeutics. Our proprietary platform leverages these natural nano-vehicles – microscopic particles released by cells that facilitate intercellular communication – to create next-generation targeted delivery systems. The company’s innovative approach combines advanced sEV selection technology with precision engineering to develop therapeutics with enhanced safety and efficacy profiles. Through our patented technology, we produce sEVs with unique molecular signatures specifically tailored to target disease pathways. By optimizing drug delivery and reducing adverse events, EVast Bio is transforming the treatment landscape for challenging diseases. Our international clinical-stage pipeline demonstrates the potential of sEV technology to revolutionize therapeutic delivery and advance precision medicine.
Speakers
Matias Vial, CEO - Cells for Cells
View all 2025 Program
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors